TheraRadar
← Back
Data updated: Mar 29, 2026

EXELA PHARMA

CardiovascularGastroenterologyNeurology
Specialty

EXELA PHARMA is a specialty pharmaceutical company focused on Cardiovascular, Gastroenterology, Neurology. Key products include GLYRX-PF.

1984
Since
20
Drugs
-
Trials
47
Approved (2yr)

Key Drugs

GLYRX-PF
glycopyrrolate
Muscarinic acetylcholine receptor 3 indications · 2018
BLOXIVERZ
neostigmine methylsulfate
Cholinesterase 1 indications · 2013
AKOVAZ
ephedrine sulfate
alpha-adrenergic receptor 1 indications · 2016
ELCYS
cysteine hydrochloride
Cystathionase 1 indications · 2019

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

CUPRIC CHLORIDE 2026-01-26
TRANEXAMIC ACID 2026-01-26
SODIUM BICARBONATE 2026-01-13
MAGNESIUM SULFATE 2026-01-08
Manufacturing (CMC)
FENTANYL CITRATE 2025-12-22
Labeling
FENTANYL CITRATE 2025-12-22
Labeling
FENTANYL CITRATE 2025-12-22
Labeling
VERAPAMIL HYDROCHLORIDE 2025-11-24
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Cardiovascular 44%
4 drugs
Gastroenterology 22%
2 drugs
Neurology 11%
1 drugs
Metabolic 11%
1 drugs
Infectious Disease 11%
1 drugs

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Merck big-pharma
Infectious Disease, Cardiovascular, Metabolic
Novo Nordisk big-pharma
Metabolic, Cardiovascular, Infectious Disease, Neurology
Johnson & Johnson big-pharma
Infectious Disease, Cardiovascular, Metabolic
AZURITY specialty
Cardiovascular, Neurology, Metabolic, Infectious Disease
WARNER CHILCOTT LLC specialty
Cardiovascular, Neurology, Gastroenterology, Infectious Disease